July 7, 2020 / 12:22 PM / a month ago

BRIEF-Outlook Therapeutics Says Completes Patient Enrollment For Norse 2 Study Of Ons-5010 / Lytenava

July 7 (Reuters) - Outlook Therapeutics Inc:

* OUTLOOK THERAPEUTICS COMPLETES PATIENT ENROLLMENT FOR NORSE 2 STUDY OF ONS-5010 / LYTENAVA™ (BEVACIZUMAB-VIKG)

* OUTLOOK THERAPEUTICS INC - PIVOTAL NORSE 2 SAFETY AND EFFICACY DATA EXPECTED TO BE REPORTED IN THIRD CALENDAR QUARTER OF 2021 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below